% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • ejohns21 ejohns21 Aug 17, 2013 11:07 AM Flag

    Institutional ownership now at 55%!

    Total ownership has gone up 10 percent in 3 months and I am definitely positive that the number is even higher now and will be reflected once data is updated upon Q3 ending. With catalysts upcoming and institutional buying going through the roof this stock is a no-brainer. Apparently buckets doom and gloom posts aren't swaying institutions decision to load up. They too must realize that the bucket is full of it.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Oh Yes! This is great news?
      The indictment alleged that a broker-dealer, White Rock Partners (later renamed State Street Capital Markets), working with brokers at several notorious boiler rooms, including J.W. Barclay & Co., A.R. Baron & Co., and D.H. Blair, engaged in microcap "pump and dump" manipulations. The indictment also alleged that the defendants most frequently relied on fraudulent Regulation S offerings to obtain their inventory of stock to manipulate.

      • 1 Reply to cigan1956
      • dens214 Aug 19, 2013 1:23 PM Flag

        March of 2000. It's 2013 now.
        State Street Corporation, or simply State Street, is a U.S.-based financial services holding company. State Street was founded in 1792, and is headquartered in the Financial District area of Boston at One Lincoln Street.[2] State Street has offices in major financial centers throughout the world.

        State Street Bank and Trust Company, a custodian bank, and its subsidiary State Street Global Advisors (SSgA), which is a registered investment advisor, constitute the principal operating companies within parent company State Street Corporation. State Street Bank provides securities services to institutional investors as a custodian bank, Investment Research and Trading and Securities Finance through the Global Markets sleeve (SSgM), and SSgA provides investment management services to mutual funds and other asset managers. State Street customers include mutual funds and their advisers, collective investment funds, corporate and public pension funds, insurance companies, operating companies and non-profit organizations.

        State Street also has an Asian presence selling a complete range of financial services, with 3,200 employees in eight cities throughout the Asia-Pacific region and headquarters located in Hong Kong.[3]

        It is the second oldest financial institution in the United States.

    • State Street Has Been Buying?

      • 1 Reply to jimkolak
      • Yes they have. Increased their position by 240 percent and is now the largest institutional shareholder. This just get better and better and the market will reflect all of this positiveness. We will break 7 bucks before the end of year SG-110 data. I have not made any calls yet on this stock but I believe this will definitely happen unless the market crashes. Calling it right now though and If I am wrong then free and bucket can rain down a bucket of #$%$ on me.

        Sentiment: Strong Buy

    • Great, as is this news:
      Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts in Transformation; Untreated Adult Acute Myeloid Leukemia
      Interventions: Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401; Drug: poly ICLC; Drug: decitabine; Other: laboratory biomarker analysis

      Celldex will benefit more than Astex though. Roswell Institute is running the trial.

      Sentiment: Strong Buy

      • 1 Reply to weightbayou
      • Pumpettees do very little research. They want to point at the institutional ownership. Great explain why the only institution that had a board member SOLD OUT of their position last quarter. Abingworth LLP sold the remaining 2,557,320 shares. If they are very close to the discussions on Astx, why would they sell all their shares. Maybe they didn't like hearing that sgi-110 maybe a second line drug at best. Maybe they didn't like that generic's on the way and expenses on the rise and revenues on the decline.

        Pumpettees do a very poor job of research. They are lazy and awkward on what they pump as news. The only institution with a seat, takes a exit on this investment. Just like you should have at $6.75 range.

        Sentiment: Sell